Examining the Efficacy of HIV Risk-Reduction Counseling on the Sexual Risk Behaviors of a National Sample of Drug Abuse Treatment Clients: Analysis of Subgroups
- PMID: 26837631
- PMCID: PMC4970956
- DOI: 10.1007/s10461-016-1300-6
Examining the Efficacy of HIV Risk-Reduction Counseling on the Sexual Risk Behaviors of a National Sample of Drug Abuse Treatment Clients: Analysis of Subgroups
Abstract
HIV counseling with testing has been part of HIV prevention in the U.S. since the 1980s. Despite the long-standing history of HIV testing with prevention counseling, the CDC released HIV testing recommendations for health care settings contesting benefits of prevention counseling with testing in reducing sexual risk behaviors among HIV-negatives in 2006. Efficacy of brief HIV risk-reduction counseling (RRC) in decreasing sexual risk among subgroups of substance use treatment clients was examined using multi-site RCT data. Interaction tests between RRC and subgroups were performed; multivariable regression evaluated the relationship between RRC (with rapid testing) and sex risk. Subgroups were defined by demographics, risk type and level, attitudes/perceptions, and behavioral history. There was an effect (p < .0028) of counseling on number of sex partners among some subgroups. Certain subgroups may benefit from HIV RRC; this should be examined in studies with larger sample sizes, designed to assess the specific subgroup(s).
Keywords: Counseling; Drug treatment; HIV; Prevention; Substance use.
References
-
- Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17. quiz CE1-4. - PubMed
-
- Boone MR, Cook SH, Wilson P. Substance use and sexual risk behavior in HIV-positive men who have sex with men: an episode-level analysis. AIDS Behav. 2013;17(5):1883–7. - PubMed
-
- Beyrer C, Wirtz AL, Baral S, Peryskina A, Sifakis F. Epidemiologic links between drug use and HIV epidemics: an international perspective. J Acquir Immune Defic Syndr. 2010;55(Suppl 1):S10–6. - PubMed
MeSH terms
Substances
Grants and funding
- UG1 DA013034/DA/NIDA NIH HHS/United States
- UG1 DA013720/DA/NIDA NIH HHS/United States
- U10 DA020036/DA/NIDA NIH HHS/United States
- P30 MH043520/MH/NIMH NIH HHS/United States
- UG1 DA013727/DA/NIDA NIH HHS/United States
- U10 DA013732/DA/NIDA NIH HHS/United States
- U10 DA013034/DA/NIDA NIH HHS/United States
- U10 DA015815/DA/NIDA NIH HHS/United States
- U10 DA013038/DA/NIDA NIH HHS/United States
- HHSN271200522071C/DA/NIDA NIH HHS/United States
- U10 DA013036/DA/NIDA NIH HHS/United States
- U10 DA013727/DA/NIDA NIH HHS/United States
- U10 DA015833/DA/NIDA NIH HHS/United States
- U10 DA013720/DA/NIDA NIH HHS/United States
- R21 DA038641/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
